161 related articles for article (PubMed ID: 17063337)
21. Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4--anaplastic lymphoma kinase gene fusion.
Meech SJ; McGavran L; Odom LF; Liang X; Meltesen L; Gump J; Wei Q; Carlsen S; Hunger SP
Blood; 2001 Aug; 98(4):1209-16. PubMed ID: 11493472
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory myofibroblastic tumor with RANBP2 and ALK gene rearrangement: a report of two cases and literature review.
Li J; Yin WH; Takeuchi K; Guan H; Huang YH; Chan JK
Diagn Pathol; 2013 Sep; 8():147. PubMed ID: 24034896
[TBL] [Abstract][Full Text] [Related]
23. Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy.
Wachter F; Al-Ibraheemi A; Trissal MC; Hollowell M; DuBois SG; Collins NB; Church AJ; Janeway KA
Pediatrics; 2021 Dec; 148(6):. PubMed ID: 34814185
[TBL] [Abstract][Full Text] [Related]
24. Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.
Giuriato S; Faumont N; Bousquet E; Foisseau M; Bibonne A; Moreau M; Al Saati T; Felsher DW; Delsol G; Meggetto F
Cancer Biol Ther; 2007 Aug; 6(8):1318-23. PubMed ID: 17660712
[TBL] [Abstract][Full Text] [Related]
25. [Inflammatory myofibroblastic tumor].
Leuschner I
Pathologe; 2010 Mar; 31(2):106-8. PubMed ID: 20063099
[TBL] [Abstract][Full Text] [Related]
26. [Inflammatory myofibroblastic tumors].
Sirvent N; Coindre JM; Pedeutour F
Ann Pathol; 2002 Dec; 22(6):453-60. PubMed ID: 12594387
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory myofibroblastic tumors of the lung carrying a chimeric A2M-ALK gene: report of 2 infantile cases and review of the differential diagnosis of infantile pulmonary lesions.
Tanaka M; Kohashi K; Kushitani K; Yoshida M; Kurihara S; Kawashima M; Ueda Y; Souzaki R; Kinoshita Y; Oda Y; Takeshima Y; Hiyama E; Taguchi T; Tanaka Y
Hum Pathol; 2017 Aug; 66():177-182. PubMed ID: 28705706
[TBL] [Abstract][Full Text] [Related]
28. FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor.
Ouchi K; Miyachi M; Tsuma Y; Tsuchiya K; Iehara T; Konishi E; Yanagisawa A; Hosoi H
Pediatr Blood Cancer; 2015 May; 62(5):909-11. PubMed ID: 25682942
[TBL] [Abstract][Full Text] [Related]
29. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract][Full Text] [Related]
30. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
[TBL] [Abstract][Full Text] [Related]
31. TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins.
Armstrong F; Lamant L; Hieblot C; Delsol G; Touriol C
Eur J Cancer; 2007 Mar; 43(4):640-6. PubMed ID: 17276053
[TBL] [Abstract][Full Text] [Related]
32. [Implications of ALK (anaplastic lymphoma kinase) in oncohematology].
Cluzeau T; Pécuchet N; Mounier N; Vignot S
Bull Cancer; 2010 Aug; 97(8):991-6. PubMed ID: 20483705
[TBL] [Abstract][Full Text] [Related]
33. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
Giuriato S; Foisseau M; Dejean E; Felsher DW; Al Saati T; Demur C; Ragab A; Kruczynski A; Schiff C; Delsol G; Meggetto F
Blood; 2010 May; 115(20):4061-70. PubMed ID: 20223922
[TBL] [Abstract][Full Text] [Related]
34. p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours.
Yamamoto H; Oda Y; Saito T; Sakamoto A; Miyajima K; Tamiya S; Tsuneyoshi M
Histopathology; 2003 May; 42(5):431-9. PubMed ID: 12713619
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
Reinhart S; Trachsel Y; Fritz C; Wagner U; Bode-Lesniewska B; John H; Pless M
Urology; 2020 Dec; 146():32-35. PubMed ID: 33007314
[TBL] [Abstract][Full Text] [Related]
36. ALK-positive anaplastic large cell lymphoma with TPM3-ALK translocation.
Shin S; Kim J; Yoon SO; Kim YR; Lee KA
Leuk Res; 2012 Jul; 36(7):e143-5. PubMed ID: 22591683
[No Abstract] [Full Text] [Related]
37. Timely topic: anaplastic lymphoma kinase (ALK) spreads its influence.
Cheuk W; Chan JK
Pathology; 2001 Feb; 33(1):7-12. PubMed ID: 11280613
[TBL] [Abstract][Full Text] [Related]
38. RET, ROS1 and ALK fusions in lung cancer.
Takeuchi K; Soda M; Togashi Y; Suzuki R; Sakata S; Hatano S; Asaka R; Hamanaka W; Ninomiya H; Uehara H; Lim Choi Y; Satoh Y; Okumura S; Nakagawa K; Mano H; Ishikawa Y
Nat Med; 2012 Feb; 18(3):378-81. PubMed ID: 22327623
[TBL] [Abstract][Full Text] [Related]
39. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
[TBL] [Abstract][Full Text] [Related]
40. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
Sasaki T; Okuda K; Zheng W; Butrynski J; Capelletti M; Wang L; Gray NS; Wilner K; Christensen JG; Demetri G; Shapiro GI; Rodig SJ; Eck MJ; Jänne PA
Cancer Res; 2010 Dec; 70(24):10038-43. PubMed ID: 21030459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]